Lateral flow assays (LFAs) are the mainstay of rapid point of care (POC) diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, there are recognised limits in terms of sensitivity and specificity when compared to tests performed in a central laboratory.
Mobile technology is touching all our lives and it’s almost inevitable that at some stage your organisation will consider developing a mobile application to tap into this emerging market. Read our blog to understand the key considerations for understanding if mobile technology is the right solution.
Developing an easy to use, sensitive over the counter (OTC) diagnostic for STIs, supported with an app-based reader with guided instructions to allow for easier self-testing, could herald a new approach to targeting sexually transmitted infections.
Secondary antibodies are a common and critical component of immunoassays. Simply stated, a secondary antibody is a reagent which recognizes an antibody of another species used to detect an analyte. A multitude of secondary antibodies are used throughout research and diagnostic applications. Secondary antibodies can be: monoclonal or polyclonal, from numerous species, directed towards any portion of the target immunoglobulin and typically direct conjugated to a reporter molecule.
Dr Stephen Pelsue, Science Director, at BBI’s custom antibody services facility discusses the fundamentals of affinity maturation and the impact on improving antibody binding for immunoassays.
In wake of the 2018 World Cup, global gatherings on such an unprecedented scale have the potential for an infectious disease outbreak. Areas where lots of people congregate offer the perfect breeding ground for norovirus.
Huge strides have been made to tackle the human immunodeficiency virus (HIV) but with recent statistics highlighting that many communities where HIV is still rife. Continued progress is needed and developing innovative diagnostics to create an effective first line of defence against HIV, is crucial.
Point of care diagnostic to distinguish between inflammatory bowel disease and irritable bowel syndrome
Inflammatory Bowel Disease (IBD) is often described as an ‘invisible’ illness. It has no known cure, affects over 300,000 people in the UK and is becoming more common especially among young people.
With mHealth apps forecast to generate $189 billion annual revenue to app providers by 2020, pharma companies hoping to jump on the mHealth bandwagon may soon find themselves facing an interesting question — how do I make money from the app?
An antigen is any structure that can be recognized by an antibody, however the binding of the antigen to an antigen receptor (membrane bound antibody) does not necessarily lead to the lymphocyte activation and the development of an immune response. A substance that has the ability to drive an immune response is referred to as an immunogen. An immunogen is also an antigen, but not all antigens are immunogens.